Publications by authors named "Marine Deslandes"
Background: Ibrutinib is a Bruton's tyrosine kinase inhibitor indicated for the first-line treatment and relapse of chronic lymphocytic leukaemia (CLL), Waldenström's macroglobulinemia (WM) and mantle cell lymphoma (MCL). This study aimed to describe the characteristics of CLL patients treated with ibrutinib and its effectiveness, safety, and treatment pattern in real life.
Methods: All patients covered by the general health scheme (approximately 80% of the French population) with a first ibrutinib dispensation from August 1, 2017 (date of reimbursement in France) to December 31, 2020, were identified in the French National Health Insurance database (SNDS).
Article Synopsis
- The FIRE observational study assessed the effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in France, with a maximum follow-up of five years post-treatment initiation.
- The study included 388 patients and found median progression-free survival (PFS) of approximately 53 months for both retrospective and prospective patients, with no significant difference in PFS for those with or without dose reductions.
- The most common adverse events were infections, with a notable percentage of patients experiencing treatment-emergent adverse events leading to death, though overall effectiveness and safety outcomes aligned with previous studies.